Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Water | HCID 962 | — |
| Reactant | Morpholine | HCID 8083 | — |
| Reactant | 1-Hydroxybenzotriazole | HCID 75771 | — |
| Reactant | HCID 86674533 | HCID 86674533 | — |
| Solvent | Dimethylacetamide | HCID 31374 | — |
| Product | HCID 89251748 | HCID 89251748 | — |
Reaction Steps
The 4-(4-tert-butoxycarbonylaminopiperidin-1-yl)-cinnamic acid (870 mg, 2.5 mmol) obtained in Example 11(1) was dissolved in N,N-dimethylacetamide (hereinafter referred to as DMA) (15 ml), and HOBt (423 mg, 2.8 mmol), WSCD (530 mg, 2.8 mmol), morpholine (241 mg, 2.8 mmol) were added thereto, followed by stirring at 80° C. for 16 hours. After cooling to room temperature, water was added to the mixture, and the precipitate was collected by filtration, thereby obtaining (3-(4-(4-tert-butoxycarbonylaminopiperidin-1-yl)-phenyl)-1-oxo-2-propen-1-yl)-morpholine (836 mg, 80%) as a white solid.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08765750B2 |
|---|
| Source dataset | uspto-grants-2014_07 |
|---|
| ORD ID | ord-9d17d14eb87d4013824f5e80d976c4a9 |
|---|
| Source note | uspto-grants-2014_07 |
|---|